Loading clinical trials...
Loading clinical trials...
Impact of Lowering Phosphate Additive Intake on Metabolism and Cardiovascular Health in Community-Living Adults (Phosphate and Fibroblast Growth Factor 23 [FGF23]: Dietary and Molecular Mediators of Health and Disparities in Cardiovascular and Kidney Diseases)
The purpose of the study is to learn more about how common food additives can affect phosphorus metabolism in people with normal kidney function and people with chronic kidney disease.
Disturbances in phosphate homeostasis are strongly associated with cardiovascular morbidity and mortality. High dietary phosphate intake plays a central role in the development of disturbed phosphate metabolism and is common in persons consuming typical American diets rich in processed and fast foods. An important reason for the high phosphate content of these foods is the widespread use of phosphate-based food additives in the food supply. Phosphate additives are heavily utilized by the food manufacturing industry to enhance the appearance, taste and shelf-life of processed foods, accounting for as much as 50% of total phosphate intake per day. Prior work from our group suggest that high phosphate additive intake has serious cardiovascular consequences. We showed that phosphate excess induces heart disease and inflammation in experimental studies, and associates with heart disease and death independently of classic risk factors in epidemiology studies. Further, we showed that high phosphate additive intake stimulates the secretion of fibroblast growth factor 23 (FGF23), a phosphate-regulatory hormone directly implicated in the pathogenesis of cardiovascular disease. Together, these data strongly suggest that high phosphate additive intake promotes cardiovascular disease, with important potential implications for efforts to reduce disparities in cardiovascular disease. This is because individuals with low socioeconomic status have limited means to purchase healthy foods, resulting in excessive consumption of processed foods rich in phosphate additives. Moreover, low income neighborhoods have a disproportionately high prevalence of individuals with chronic kidney disease and black individuals, both groups that have impaired ability to excrete excess phosphate. Together, these data support our overriding hypothesis that high phosphate additive intake is a novel target for reducing socioeconomic and racial disparities in cardiovascular. We will test this hypothesis in detailed feeding studies of 80 individuals fed standardized meals with low phosphate additive content for 6 weeks. We will investigate the impact of reducing phosphate additive intake on changes in FGF23 levels, inflammatory markers and vascular function, and test for effect modification by race and chronic kidney disease (CKD). The results of these studies will help determine whether high phosphate additive intake is a modifiable risk factor for disparities in cardiovascular disease.
Age
18 - No limit years
Sex
ALL
Healthy Volunteers
Yes
University of Alabama
Birmingham, Alabama, United States
Start Date
August 28, 2015
Primary Completion Date
March 5, 2020
Completion Date
March 30, 2020
Last Updated
March 11, 2021
50
ACTUAL participants
Diet
OTHER
Lead Sponsor
University of Alabama at Birmingham
NCT07241390
NCT06290258
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions